Iagree there was not much new news, but positive Subsequent Events. Particularly the following statements, which, to me, means that their "proprietary [patented, i.e., CLONE3] mAbs" covers the waterfront in curing/treating HIV-AIDS, COVID, & other viral infectious diseases: (See Pg 22)
"The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody
(identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully
neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its
broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The
targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the
87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).
Using AI, the Company has also identified 8 additional conserved sites on the HIV-1 virus, some with over
98% conserved sequences, against which the Company plans to produce anti-HIV monoclonal antibodies.
Production of multiple antibodies targeting different conserved and expectedly immutable sites comports with
experts’ conclusion that an effective treatment for HIV and the Coronavirus will likely require the
administration of multiple monoclonal additional antibodies. Effective monoclonal antibodies will be those
that target conserved and expectedly immutable virus sites. Producing targeted antibodies will result in the
production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. In other
words, even a “variant form of the virus” will expectedly contain the immutable targeted sites. Targeting
immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site
that nutates.
While the Company’s HIV therapeutics may be used as an immunotherapeutic treatment for individuals with
HIV/AIDS, they may also be developed for use as a prophylactic and therapeutic vaccine to prevent
uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will
be far superior to current antiretroviral therapy for several significant reasons:
(1) the therapy will be non-toxic (without damage to the kidneys and liver) and will not cause bone density
deterioration (osteopenia and osteoporosis) – as does antiretroviral treatments, (2) will not require lifetime
treatment and (3) will be far less expensive.
Using its proprietary methodology, the Company is also producing anti-SARS-CoV-2 monoclonal antibodies
and has identified 19 conserved, expectedly immutable epitopes on the Coronavirus against which it plans
to produce targeted monoclonal antibodies. Using AI, the Company has screened over 2.8 million Coronavirus
isolates currently known and has identified conserved sites which expectedly are immutable. The 19 conserved
sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to
99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed by the Company using AI.
Comprehensive patent protection covering these discoveries, relating to HIV, the Coronavirus, and use of AI
to guide production of antibodies have been filed under the Patent Cooperation Treaty (PCT) to seek coverage
in the U.S. and in member countries of the PCT, In these PCT Patent Applications, the Company has claimed
its discoveries relating to both HIV and the SARS CoV-2 (Coronavirus) including the use of these identified
conserved epitopes for (1) producing a therapeutic monoclonal antibody to treat HIV or the CoronaVirus, (2)
producing a vaccine against HIV or the CoronaVirus, or (3) for use in any diagnostics to identify whether a
person has HIV or the CoronaVirus. In this way, the patent coverage sought includes patent claims on the
discovered epitope/antigens, vaccine claims, antibody claims, and related prophylactic/therapeutic method
claims relating to the epitope/antigens."
ALSO IMPORTANT:
"The Coronavirus treatment drug market is expected to grow from 15.9 billion in 2020 to over $49.2 billion in
2027. The HIV Drug Market is expected to reach $36.49 billion by 2027 for a total market size of $85.69 for the
treatments under development, The Company expects, aided by the continued use of AI, further expansion
of its pipeline of additional treatments for other life threatening and debilitating viruses both in humans and
in animals.
"
News 
Market Data 
Discover 
